HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Advances in the detection of residual thyroid carcinoma.

Abstract
The challenge of detecting and anatomically localizing metastatic thyroid cancer deposits has become less daunting with the recent developments in radionuclide technology. The use of serum Tg measurements and the whole body radioiodine scan remain the mainstays of the diagnostic evaluation. The advent of recombinant human TSH makes the preparation for a diagnostic scan much less burdensome and appears to have excellent sensitivity for serious metastatic lesions. The dilemma of an elevated serum Tg associated with a negative DxWBS has been ameliorated somewhat with the newly discovered ability of FDG-PET scanning to localize these less well-differentiated lesions. The real challenge lies in the development of new therapeutic agents to treat metastatic lesions that do not concentrate radioiodine.
AuthorsR Robbins, W Drucker, L Hann, R M Tuttle
JournalAdvances in internal medicine (Adv Intern Med) Vol. 46 Pg. 277-94 ( 2001) ISSN: 0065-2822 [Print] United States
PMID11147255 (Publication Type: Journal Article, Review)
Topics
  • Carcinoma (diagnosis, surgery)
  • Diagnostic Imaging (methods)
  • Female
  • Humans
  • Male
  • Neoplasm, Residual (diagnosis)
  • Sensitivity and Specificity
  • Thyroid Neoplasms (diagnosis, surgery)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: